Advaxis collaborates with UBC to develop live attenuated Listeria vaccines

Advaxis, Inc., (OTCBB: ADXS), the live, attenuated Listeria monocytogenes (Listeria) immunotherapy company, has entered into a structured collaboration with the laboratory of Dr. Tobias Kollmann at the University of British Columbia (UBC) to develop live attenuated Listeria vaccines for the treatment of infectious disease and for new dosage forms of Listeria vaccines.

The same immune-stimulating properties that are under development at Advaxis to develop live Listeria vaccines as safe and effective therapies for the treatment of cancer, also may have application for the treatment of infectious disease. Dr. Kollmann is an immunologist and neonatal vaccinologist who has published extensively on the use of Listeria vaccines as potential therapeutic agents for the treatment of childhood diseases.

Under the terms of this collaboration, Dr. Kollmann will use Advaxis proprietary Listeria vaccine vectors for the development of novel infectious disease applications, and employ a post-doctoral fellow who will be dedicated to the creation and assessment of novel infectious disease vaccines and new delivery forms of live attenuated Listeria vaccines.